



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/735,401 12/12/2000		Eckhard Alt	IFD/046	4641
490	490 7590 02/03/2004		EXAMINER	
•	RRETT & STEINKRA	THALER, MICHAEL H		
6109 BLUE CIRCLE DRIVE SUITE 2000 MINNETONKA, MN 55343-9185			ART UNIT	PAPER NUMBER
			3731	0.72
			DATE MAILED: 02/03/2004	27

Please find below and/or attached an Office communication concerning this application or proceeding.

bu C	
КĎ	
e address	
timely. his communication.	
o the merits is	
a). 7 CFR 1.121(d). 1 PTO-152.	
nal Stage	
onal application) tion Data Sheet.	
nce a specific 37 CFR 1.78.	

		th/
	Application No.	Applicant(s)
	09/735,401	ALT, ECKHARD
Office Action Summary	Examiner	Art Unit
	Michael Thaler	3731
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	I36(a). In no event, however, may a reply be till by within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE.	mely filed ys will be considered timely. the mailing date of this communication. ED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on <u>08 D</u>	December 2003.	
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.	
3) Since this application is in condition for allowal closed in accordance with the practice under E		
Disposition of Claims		
<ul> <li>4)  Claim(s) 61,64,65 and 68-85 is/are pending in 4a) Of the above claim(s) 83 and 84 is/are with 5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 61,64,65,68-82 and 85 is/are rejected 7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/o</li> </ul>	ndrawn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. §§ 119 and 120		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 13) Acknowledgment is made of a claim for domestic since a specific reference was included in the first 37 CFR 1.78.  a) The translation of the foreign language process.	is have been received. Its have been received in Applicate rity documents have been received (PCT Rule 17.2(a)). In of the certified copies not receive ic priority under 35 U.S.C. § 119(set sentence of the specification of the priority under 35 U.S.C. § 120(b).	ion No ed in this National Stage ed. e) (to a provisional application) r in an Application Data Sheet. ceived. and/or 121 since a specific
Attachment(s)		
1) Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Information Disclosure Statement(s) (PTO-1449) Paper No(s) 2	5) Notice of Informal F	r (PTO-413) Paper No(s) Patent Application (PTO-152)

Application/Control Number: 09/735,401

Art Unit: 3731

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on Dec. 8, 2003 has been entered.

Claims 83 and 84 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

61, 64, 65 and 68-82 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In claim 61, line 7, there is no antecedent basis for "said struts". Also, in claim 61, line 7, "having a cross-section substantially of the shape of an erythrocyte" is indefinite since a cross-section, which has two dimensions, cannot have a shape of a structure which has three dimensions (such as an erythrocyte). For example, a cross section may have a shape of a square (which has two dimensions) but may not have of a cube (which has three dimensions). Claim 65 is indefinite for the same reason. As to claim 69, line 1,

Art Unit: 3731

"further comprising a plurality of serpentine bands", is indefinite since the struts which form the serpentine bands have already been claimed in claim 61, resulting in a double recitation of the same element. Claim 76 is indefinite for the same reason.

Claims 61, 64, 65, 68-71, 76-78 are rejected under 35 U.S.C. 102(b) as being anticipated by Fontaine (5,370,683). Fontaine, in figures 10-12, shows a stent having a wall with a multiplicity of holes formed therethrough, the tubular wall defined by a plurality of struts. As to the phrase "having a cross-section substantially of the shape of an erythrocyte" (as best understood) in claim 61, line 7, an erythrocyte has a shape (or filled-in circle) when viewed a disk appropriated direction. Fontaine shows the cross-section of the struts as circular (i.e. a filled-in circle), thus meeting this term as broadly claimed. As to claims 69 and 76, Fontaine discloses a plurality of serpentine bands (each of the windings of the helical coil), each of the bands being a continuous structure (since they are formed of a single piece of material) and a closed structure (Each winding forms a ring which is closed since it is attached to the adjacent winding. Each ring is closed in the same sense that a conventional key ring formed of a helical wire is closed). As to claims 71 and 78, Fontaine Art Unit: 3731

shows a connector (one of the intermediate windings of the helical coil).

Claims 72, 73, 79, 80 and 85 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fontaine (5,370,683) in view of Sawyer (5,108,417). Fontaine fails to disclose the claimed taper. However, Sawyer teaches that a stent should have a taper (figure 3) in order to increase the velocity of the blood and thus reduce the possibility of thrombosis (col. 4, lines 26-54). It would have been obvious to include a taper in the Fontaine stent so that it too would have this advantage. As to claim 85, the Sawyer stent tapers from the midpoint to one end of the stent at a substantially constant slope in relation to the longitudinal axis.

Claims 74, 75, 81 and 82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fontaine (5,370,683) in view Marin et al. (5,397,355). Fontaine fails to disclose the claimed taper. However, it is well known in this art to provide a taper the exterior surface of stents. For example, Marin et al. teach that the outer diameter of a stent should have a taper (at 18) in order to anchor the stent within the blood vessel and also facilitate smooth passage within a blood vessel when barbs 18 are unexpanded. It would have been obvious to include a

Application/Control Number: 09/735,401

Art Unit: 3731

taper in the Fontaine stent (i.e. barbs which form a taper in

the stent) so that it too would have this advantage.

Applicant's arguments filed Dec. 8, 2003 have been fully

considered but they are not persuasive for the reasons set forth

above.

Any inquiry concerning this communication or earlier

communications from the examiner should be directed to Michael

Thaler whose telephone number is (703) 308-2981. The examiner

can normally be reached Monday to Friday.

If attempts to reach the examiner by telephone are

unsuccessful, the examiner's supervisor, Michael J. Milano can

be reached on (703)308-2496. The fax phone number for the

organization where this application or proceeding is assigned is

(703)872 - 9306.

Any inquiry of a general nature or relating to the status

of this application or proceeding should be directed to the

receptionist whose telephone number is (703)308-0858.

mht 1/30/04 MICHAEL THALER
PRIMARY EXAMINER

ART UNIT 3731

Page 5